JaLCDOI 10.18926/AMO/57379
フルテキストURL 73_5_469.pdf
著者 Yamasaki, Satoshi| Kada, Akiko| Nagai, Hirokazu| Yoshida, Isao| Choi, Ilseung| Saito, Akiko M.| Iwasakia, Hiromi|
抄録 Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine, dexamethasone, and cisplatin (GDP). GDP therapy will be administered every 3 weeks. If complete response, partial response, or stable disease is confirmed after 2-4 GDP cycles, romidepsin will be administered every 4 weeks. The primary endpoint is a 2-year progression-free survival rate. Patients participating in this study and undergoing treatment can expect results similar to or better than those of conventional therapies.
キーワード peripheral T-cell lymphoma not otherwise specified angioimmunoblastic T-cell lymphoma gemcitabine cisplatin, romidepsin
Amo Type Clinical Study Protocol
発行日 2019-10
出版物タイトル Acta Medica Okayama
73巻
5号
出版者 Okayama University Medical School
開始ページ 469
終了ページ 474
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 31649375
Web of Sience KeyUT 000491886600014
JaLCDOI 10.18926/AMO/56079
フルテキストURL 72_3_315.pdf
著者 Miyata, Yasuhiko| Saito M. , Akiko| Yano, Takahiro| Yoshida, Isao| Suehiro, Youko| Harada, Naoki| Nagai, Hirokazu|
抄録 In very-elderly diffuse large B-cell lymphoma (DLBCL) patients, treatment intensities must be lowered due to the risks of comorbidities and organ function deterioration, and treatment outcomes are worse compared to younger patients. Very-elderly patients are often excluded from DLBCL clinical trials, and optimal treatments and dosages are not established. In this clinical trial, we examined the efficacy and safety of 6 courses of R-mini CHP therapy (cf., CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone]) in which vincristine is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life, as remission induction therapy in DLBCL patients aged≥80 years.
キーワード rituximab diffuse large B-cell lymphoma open-label single arm trial
Amo Type Clinical Study Protocol
発行日 2018-06
出版物タイトル Acta Medica Okayama
72巻
3号
出版者 Okayama University Medical School
開始ページ 315
終了ページ 318
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29926011
JaLCDOI 10.18926/AMO/55863
フルテキストURL 72_2_197_n.pdf
著者 Takase, Ken| Kada, Akiko| Iwasaki, Hiromi| Yoshida, Isao| Sawamura, Morio| Yoshio, Nobuyuki| Yoshida, Shinichiro| Iida, Hiroatsu| Otsuka, Maki| Takafuta, Toshiro| Ogata, Yuko| Suehiro, Youko| Hirabayashi, Yukio| Hishita, Terutoshi| Yoshida, Chikamasa| Ito, Takuo| Hidaka, Michihiro| Tsutsumi, Ikuyo| Saito, Akiko M.| Nagai, Hirokazu|
抄録 Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of <20, 000 /μL, or with <50, 000/ μL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.
キーワード idiopathic thrombocytopenic purpura short-term high-dose dexamethasone therapy open-label single-arm trial
Amo Type Clinical Study Protocol
発行日 2018-04
出版物タイトル Acta Medica Okayama
72巻
2号
出版者 Okayama University Medical School
開始ページ 197
終了ページ 201
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29674771